Genelux Corporation (GNLX)
| Market Cap | 129.67M +22.0% |
| Revenue (ttm) | 8,000 |
| Net Income | -33.58M |
| EPS | -0.85 |
| Shares Out | 44.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,801 |
| Open | 2.940 |
| Previous Close | 2.920 |
| Day's Range | 2.860 - 2.950 |
| 52-Week Range | 2.290 - 8.535 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 17.50 (+499.32%) |
| Earnings Date | May 7, 2026 |
About GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product... [Read more]
Financial Performance
In 2025, Genelux's revenue was $8,000, a change of 0.00% compared to the previous year's $8,000. Losses were -$32.15 million, 7.62% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GNLX stock is "Strong Buy." The 12-month stock price target is $17.5, which is an increase of 499.32% from the latest price.
News
Genelux reports Q1 EPS (20c), consensus (19c)
“As we build on our momentum entering 2026, we remain focused on disciplined execution of our registrational program. The randomized Phase 3 OnPrime/GOG-3076 trial remains on track for topline data…
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected...
Genelux price target lowered to $20 from $23 at Benchmark
Benchmark lowered the firm’s price target on Genelux (GNLX) to $20 from $23 and keeps a Speculative Buy rating on the shares after adjusting the firm’s sum-of-the-parts analysis for the…
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in r...
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and ...
Genelux prices 6.67M shares at $3.00 in underwritten public offering
Genelux (GNLX) Corporation announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of…
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritte...
Genelux announces common stock offering, no amount given
Genelux (GNLX) Corporation announced that it has commenced a proposed underwritten public offering of its common stock. All shares are being offered by Genelux. Lucid Capital Markets is acting as…
Genelux Corporation Announces Proposed Public Offering of Common Stock
WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a propo...
Genelux data update indicates disease early control, says H.C. Wainwright
Genelux (GNLX) reported updated interim data showing IV Olvi-Vec plus platinum chemotherapy achieved a 33% overall response rate and 67% disease control rate in heavily pretreated platinum-relapsed/re...
Genelux reports interim data of systemic administration of Olvi-Vec
Genelux (GNLX) announced interim results from two ongoing trials – Phase 1b/2 SCLC and Phase 2 VIRO-25 – evaluating systemic administration of Olvi-Vec in patients with progressive small cell lung…
Genelux appoints Jason Litten as CMO
Genelux (GNLX) Corporation announced the appointment of Jason Litten as Chief Medical Officer, effective January 2. Dr. Litten will oversee all clinical development and medical strategy as the company...
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., a...
Genelux reports Q3 EPS (21c), consensus (21c)
“In the third quarter, we continued to progress Olvi-Vec’s development across multiple solid tumor indications, positioning the program for meaningful clinical milestones and key catalysts in the comi...
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --
Genelux initiated with a Buy at Titan Partners
Titan Partners analyst Boris Peaker initiated coverage of Genelux (GNLX) with a Buy rating and $20 price target The development-stage biotechnology company has an oncolytic viral therapy in a pivotal…
Genelux price target raised to $20 from $10 at Maxim
Maxim raised the firm’s price target on Genelux (GNLX) to $20 from $10 and keeps a Buy rating on the shares. The firm is lowering its risk adjustment for olvimulogene…
Genelux initiated with a Buy at Lake Street
Lake Street analyst Chad Messer initiated coverage of Genelux (GNLX) with a Buy rating and $16 price target The pivotal readout for olvimulogene nanivacirepvec, or olvi-vec, in ovarian cancer, due…
Genelux reports Q2 EPS (20c), consensus (22c)
“With important data milestones on the horizon, Olvi-Vec holds the potential to redefine the treatment paradigms of recurrent tumors in multiple indications, as well as the broader field of oncolytic…
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter ...
Genelux initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Genelux (GNLX) with a Buy rating and $10 price target Genelux is a late clinical-stage biotechnology company focused on utilizing oncolytic viral immunotherapies fo...
Genelux appoints Eric Groen as general counsel, corporate secretary, CCO
Genelux Corporation (GNLX) announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development. Most recently, Mr. Groen served a...
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General ...
Genelux reports Q1 EPS (21c), consensus (24c)
“The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications,…
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of...